-
Lundbeck’s Vyepti Migraine Treatment Available at Sun Yat-sen Memorial Hospital Through Greater Bay Area Policy
•
Vyepti (eptinezumab), a migraine treatment developed by Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF), has been introduced at Sun Yat-sen Memorial Hospital, Sun Yat-sen University, facilitated by the “Hong Kong-Macau Drug and Device Access” policy. This policy, part of the broader Greater Bay Area initiative, enables patients to access…
-
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
•
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the H1 2023 period, reporting a 10% year-on-year (YOY) increase in sales revenues in constant exchange rate terms, reaching DKK 10 billion (USD 1.45 billion) over the six-month period. CEO Deborah Dunsire celebrated the “excellent performance,”…
